Tirzepatide remade the body in the trials — fat lost, lean mass mostly kept.

Before the details

Tirzepatide is a prescription medicine, FDA-approved since 2022, that works by mimicking two gut hormones your body already makes — called GIP and GLP-1 (glucagon-like peptide-1) — that normally signal "enough" after a meal. By activating both signals at once, it reduces hunger and food intake more powerfully than medicines that activate only one. In the largest clinical trials, people lost roughly 15–21% of their body weight over about 18 months. Of the weight they lost, about three-quarters was fat and one-quarter was lean mass — meaning some muscle is lost alongside fat, which is a common pattern with potent weight-loss therapies. The most common side effects are nausea, constipation, and diarrhea, especially when the dose is first raised. It is given as a once-weekly injection under the skin. This site summarises the peer-reviewed literature — what the studies measured, what remains uncertain, and what people who have used it in real life have reported. For what people report — including the downsides — see the effects page.

Timeline: FDA-approved for type 2 diabetes (May 2022), obesity (November 2023), and obstructive sleep apnea in adults with obesity (2024) ^[1][7].

What is tirzepatide

Tirzepatide is a 39-amino-acid synthetic peptide — a tirzepatide peptide built on the backbone of the native GIP hormone, modified with a C20 fatty diacid arm that binds albumin in the bloodstream, extending its elimination half-life to approximately five days and enabling once-weekly dosing ^[1][2]. Molecular formula C225H348N48O68, molecular weight 4813.53 Da, CAS 2023788-19-2. It activates both the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R), the two principal incretin (gut-to-pancreas signalling) receptors ^[1][2]. In signalling assays, it engages the GIP receptor more fully than the GLP-1 receptor — what researchers call an imbalanced dual agonist — and shows biased GLP-1R signalling that favours cyclic AMP (the internal signal that triggers insulin release) over the beta-arrestin pathway that tends to reduce receptor sensitivity ^[2].

What does tirzepatide do in the body? Activating both receptors simultaneously enhances glucose-dependent insulin secretion, suppresses glucagon (the hormone that raises blood sugar), slows gastric emptying (the stomach empties more slowly after meals, prolonging the sense of fullness), and reduces appetite via central nervous system signals. GIP and GLP-1 receptors are expressed not only in the pancreas but across liver, muscle, adipose tissue, the brain, the heart, the immune system, and the kidneys — the basis for tirzepatide's broad cardiometabolic effects ^[10].

The body-composition record: what the trials measured

The landmark finding that defines this site's lens: in the SURMOUNT-1 DXA body-composition substudy (n=160), tirzepatide at 72 weeks produced a mean body-weight change of -21.3% versus -5.3% for placebo. Of the weight lost with tirzepatide, approximately 75% was fat mass and approximately 25% was lean mass ^[11]. Fat mass fell 33.9%; lean mass fell 10.9% ^[11]. Both proportions were consistent across most subgroup analyses, including by sex, age, and baseline BMI.

A 2024 narrative review in Diabetes Care placed the lean-mass fraction in context: across incretin-based therapies, roughly 15–24% of total weight lost was lean mass — similar to older bariatric interventions — and estimated the rapid lean-mass loss as comparable to a decade or more of ageing, recommending resistance exercise training as an evidence-based adjunct ^[12]. A 2025 systematic review further characterised the skeletal-muscle picture during tirzepatide-induced weight reduction ^[5].

For the fat-distribution specifics, the SURPASS-3 MRI substudy (n=296) compared tirzepatide with insulin degludec in people with type 2 diabetes. Liver fat content fell from a mean baseline of 15.71% by an absolute 8.09 percentage points with pooled tirzepatide 10/15 mg versus 3.38 with insulin degludec (treatment difference -4.71%; P<0.0001) ^[8]. Tirzepatide also preferentially reduced visceral adipose tissue volume and shifted the overall fat-distribution pattern toward population norms by week 52 — elevated visceral (z-VAT -0.18; P<0.001) and liver fat (z-LF -0.54; P<0.001) fell while subcutaneous fat normalised ^[9]. The finding matters: visceral fat — the fat packed around internal organs — is the metabolically active fraction linked to insulin resistance and cardiovascular risk.

See the full breakdown on the dedicated tirzepatide muscle loss page.

What the SURMOUNT weight-loss trials found

SURMOUNT-1 (n=2539, 72 weeks) was the defining obesity trial. Adults without diabetes, with a BMI of 30 or higher (or 27+ with a weight-related complication), received once-weekly tirzepatide at three maintenance doses or placebo after a 20-week stepwise escalation. Mean weight change at week 72 was -15.0% (5 mg), -19.5% (10 mg), and -20.9% (15 mg) versus -3.1% with placebo ^[4]. The proportions reaching >=15% weight loss were 40%, 57%, and 62% at the three doses versus 7% with placebo.

SUMMOUNT-5 (n=751) provided the first head-to-head randomised comparison of tirzepatide with another approved agent for obesity. Adults without type 2 diabetes were randomised to the maximum tolerated dose of tirzepatide (10 or 15 mg) or the maximum tolerated dose of a comparator GLP-1 receptor agonist once weekly for 72 weeks. Mean weight change: -20.2% with tirzepatide versus -13.7% with the comparator (P<0.001); tirzepatide also produced a greater reduction in waist circumference and higher proportions reaching >=10%, >=15%, >=20%, and >=25% weight loss ^[5].

See tirzepatide weight loss for the full trial-by-trial account and cardiometabolic follow-on data.

Tirzepatide results: cardiometabolic and beyond-weight outcomes

The cardiometabolic dividends of tirzepatide results scale with the degree of weight loss. A post hoc SURMOUNT-1 analysis (n=1605) found that participants losing >=35% body weight achieved mean improvements of systolic blood pressure -14.2 mmHg, waist circumference -32.4 cm, and HOMA-IR -59.7% (a measure of insulin resistance). Improvements in insulin resistance and blood glucose markers were detectable even with modest weight loss of less than 5%, whereas lipid improvements (triglycerides, HDL, LDL) appeared primarily after >10% weight reduction ^[13].

The SURPASS-CVOT trial (n>14,000) completed in 2025 and compared tirzepatide with an established GLP-1 receptor agonist in adults with type 2 diabetes and atherosclerotic cardiovascular disease ^[16]. Propensity-matched real-world US cohort studies found comparable cardiovascular benefit between tirzepatide and the comparator GLP-1 agonist in clinical practice ^[17]. Beyond glycaemia and body weight, the SYNERGY-NASH trial (n=190) found higher rates of MASH (metabolic dysfunction-associated steatohepatitis, formerly NASH — a progressive fatty liver disease) resolution without worsening of fibrosis with tirzepatide versus placebo ^[14], and the SURMOUNT-OSA trial found a reduction in apnea-hypopnea index of 25.3 events/hour (in participants not using a CPAP device) versus approximately 5 events/hour with placebo over 52 weeks ^[15].

Tirzepatide reviews: what people report

Clinical-trial data captures outcomes measured at defined endpoints; the patient experience between those points is documented in structured exit interviews and post-market pharmacovigilance. Frequently described benefits include a dramatic quieting of food-related preoccupation — 79–91% of SURMOUNT trial participants cited reduced appetite as a top benefit — and improved energy and confidence in roughly 62–79% and 47–55% of structured interviews respectively. Frequently reported side effects are gastrointestinal: nausea affects roughly 25–50% of community users, most intensely in the first one to two weeks after each dose increase; constipation and diarrhoea commonly alternate as the stomach adjusts to the drug's slowing effect on gastric emptying. Hair thinning (telogen effluvium — a recognised, generally reversible response to rapid weight loss) has been reported by a subset of users, typically three to six months after starting.

The full account — benefits, adverse effects, and safety cautions, all cited — is on the Tirzepatide effects page.